Treatment Response Assessment According to Updated PROMISE Criteria in Patients with Metastatic Prostate Cancer Using an Automated Imaging Platform for Identification, Measurement, and Temporal Tracking of Disease

By sjmartinez • November 14, 2024

Benitez CM, Sahlstedt H, Sonni I, Brynolfsson J, Berenji GR, Juarez JE, Kane N, Tsai S, Rettig M, Nickols NG, Duriseti S. Treatment Response Assessment According to Updated PROMISE Criteria in Patients with Metastatic Prostate Cancer Using an Automated Imaging Platform for Identification, Measurement, and Temporal Tracking of Disease. Eur Urol Oncol. 2024 Nov 8:S2588-9311(24)00240-2. doi: 10.1016/j.euo.2024.10.011. Epub ahead of print. PMID: 39521638.

Tags: Artificial intelligence, Automated, Hematology/Oncology, Positron emission tomography, prostate-specific membrane antigen, Publications, Veterans Administration

Prediction of Early Neoadjuvant Chemotherapy Response of Breast Cancer through Deep Learning-based Pharmacokinetic Quantification of DCE MRI

Wu C, Wang L, Wang N, Shiao S, Dou T, Hsu YC, Christodoulou AG, Xie Y, Li D. Prediction of Early Neoadjuvant Chemotherapy Response of[...]

Addressing the Unmet Need for Treatment in Advanced Hepatocellular Carcinoma With Child-Pugh C Cirrhosis: A Case of a Woman With Hepatocellular Carcinoma and Advanced Liver Disease

Chamberlain E, Cleveland JM. Addressing the Unmet Need for Treatment in Advanced Hepatocellular Carcinoma With Child-Pugh C Cirrhosis: A Case of a Woman With Hepatocellular[...]

Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial

Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE 3rd, Wada DA, Plaza JA, Sosman JA, In GK, Ikeguchi A, Hyngstrom J,[...]